A Phase 1 Trial of Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 21 Nov 2018
Price : $35 *
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Nov 2018 Status changed from active, no longer recruiting to completed.
- 09 May 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
- 09 May 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History